Novo Nordisk Taiwan is reframing obesity from weight loss to long-term health, emphasizing prevention, early intervention, and collaboration across Taiwan’s healthcare system. Through awareness, screening, and employee support, the company is helping advance a broader approach to metabolic health.
Taiwan’s growing obesity challenge is fueling interest in weight-loss medication, along with fresh questions about access, safety, and long-term care.
With more than half of Taiwan’s adults classified as overweight or obese, experts are calling for systemic reforms that start with childhood education, food policy, and lifestyle habits. Tackling the country’s growing health crisis requires coordinated efforts across schools, families, and government to build a healthier future.
Novo Nordisk Taiwan is transforming the way obesity is understood and treated, pushing beyond weight loss to position it as a chronic disease that demands urgent, long-term care. With cutting-edge research, public health partnerships, and advocacy to fight stigma, the company is driving a systemic shift in how Taiwan addresses one of its most pressing health challenges.
